1. Which of the following drugs is provided to human patients only as a compounded preparation and to veterinary patients as an FDA-approved product?
A. Diethylstilbestrol
B. Estriol
C. Pergolide mesylate
D. Phenylpropanolamine
2. Which of the following statements regarding trilostane therapy in animals is correct?
A. Trilostane is a pregnancy Category X drug and may not be used in pregnant animals.
B. The dosage that veterinarians typically use to initiate treatment for dogs with hyperadrenocorticism is significantly higher than the labeled dose.
C. Trilostane has been used off-label to treat Alopecia X, a disease that affects certain cat breeds.
D. If an alternate dosage form must be compounded—for example, an oral suspension—the bulk drug powder should be used as the source of active ingredient, because the capsules are difficult to empty completely and may result in a subtherapeutic concentration.
3. Which of the following does not represent a common use of domperidone in horses?
A. As a prokinetic agent to stimulate gastric motility
B. For prevention of fescue toxicosis in pregnant mares near term
C. To aid in diagnosis of pituitary pars intermedia dysfunction (PPID)
D. To induce lactation in non-pregnant nurse mares for orphaned foals
4. Which of the following statements regarding oclacitinib is correct?
A. Oclacitinib is a monoclonal antibody approved for use in cats.
B. Because the oral bioavailability of oclacitinib is low, it must be administered by subcutaneous injection.
C. Compounded dosage forms may be prepared using oclacitinib base, the maleate salt, or the citrate salt.
D. Pet owners should contact a veterinarian immediately if they notice signs of infection or skin growths on a treated animal.
5. Which of the following statements regarding maropitant is not correct?
A. Maropitant is a neurokinin-1 receptor antagonist that blocks the action of Substance P in the central nervous system.
B. Maropitant is used to prevent vomiting in dogs and cats.
C. Maropitant should not be administered for more than 5 consecutive days to avoid potential drug accumulation.
D. Refrigerating maropitant solution may decrease pain and stinging during subcutaneous injection.
6. Which of the following statements regarding cisapride is correct?
A. Cisapride is an anticholinergic agent used to manage gastroparesis in animals.
B. Cisapride is excreted primarily as unchanged drug in the urine.
C. Rectal administration is the most effective route of administration in horses.
D. Cisapride must be compounded for veterinary use, and USP has published validated compounding formulas for both cisapride oral suspension and cisapride injection.
7. Potassium bromide should not be administered concurrently with which of the following drugs?
A. Sodium bicarbonate.
B. Sodium chloride.
C. Potassium citrate.
D. Sodium citrate.
8. Pimobendan exerts its effect on heart rate through which of the following mechanisms?
A. It is a negative inotrope.
B. It is a phosphodiesterase 3 inhibitor.
C. It is a calcium channel blocker.
D. It is a β-blocker.
9. Which of the following statements regarding clenbuterol is correct?
A. Clenbuterol is used to manage airway obstruction in horses, dogs, and cats.
B. Bradycardia is a common adverse effect during treatment with clenbuterol.
C. Use of clenbuterol is banned in competitive human athletes and food-producing animals.
D. Clenbuterol should never be administered to pregnant mares near term.
10. Phenylpropanolamine is used commonly in dogs for which of the following indications?
A. Hypotension
B. Nasal decongestion
C. Urinary incontinence
D. Weight loss
Evaluation Questions
11. To what extent did the program meet objective #1?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
12. To what extent did the program meet objective #2?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
13. To what extent did the program meet objective #3?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
14. To what extent did the program meet objective #4?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
15. Rate the effectiveness of how well the program related to your educational needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
16. Rate how well the active learning strategies (questions, cases, discussions) were appropriate and effective learning tools:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
17. Rate the quality of the faculty:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
18. Rate the effectiveness and the overall usefulness of the material presented:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
19. Rate the appropriateness of the examination for this activity:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
20. Rate the effectiveness of how well the activity related to your practice needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
21. Rate the effectiveness of how well the activity will help you improve patient care:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
22. Will the information presented cause you to change your practice?
A. Yes
B. No
23. Are you committed to making these changes?
A. Yes
B. No
24. As a result of this activity, did you learn something new?
A. Yes
B. No
25. What is your practice setting or area of practice?
A. Community Pharmacy/Independent
B. Community Pharmacy/Chain
C. Hospital/Health Systems
D. Administrative/Pharmacy Director
E. Critical Care Pharmacy
F. Long-term Care
G. Managed Care/PBM
H. Oncology
I. Specialty Pharmacy
J. Industry/Manufacturing
26. How many years have you been in practice?
A. <5
B. 5 – 10
C. 11 – 20
D. >20
